Adverem Biotechnologies: Gene Therapy Company And Our New Buy – Seeking Alpha
Seeking Alpha |
Adverem Biotechnologies: Gene Therapy Company And Our New Buy
Seeking Alpha We bought shares of Adverem Biotechnologies (ADVM). The stock is at an attractive entry point ahead of phase I/II data from a gene therapy trial in alpha-1 antitrypsin deficiency in the second half of this year. We are rating the stock a Buy with price … Adverum Biotechnologies Inc. (ADVM) Plunges 6.03% on April 06 Analysts' Weekly Ratings Changes for Adverum Biotechnologies (ADVM) Adverum Biotechnologies (NASDAQ:ADVM) Downgraded to Hold at Zacks Investment Research |
